Completed PHASE3 INTERVENTIONAL 2-arm NCT00345839

E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events (EVOLVE)

EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events

Sponsor: Amgen

Conditions Chronic Kidney Disease Secondary Hyperparathyroidism

Updated 10 times since 2017 Last updated: Nov 3, 2022 Started: Aug 22, 2006 Primary completion: Apr 10, 2012 Completion: Apr 10, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00345839, this PHASE3 trial focuses on Chronic Kidney Disease and Secondary Hyperparathyroidism and remains completed. Sponsored by Amgen, it has been updated 10 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2022 — Jul 2024 [monthly]

Completed PHASE3
Sep 2022 — Dec 2022 [monthly]

Completed PHASE3
Jan 2021 — Sep 2022 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

May 2019 — Jan 2021 [monthly]

Completed PHASE3
Nov 2018 — May 2019 [monthly]

Completed PHASE3
Sep 2018 — Nov 2018 [monthly]

Completed PHASE3
Jun 2018 — Sep 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.